{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:00:46Z","timestamp":1784818846111,"version":"3.55.0"},"reference-count":27,"publisher":"Xia & He Publishing","issue":"1","license":[{"start":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T00:00:00Z","timestamp":1623715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.xiahepublishing.com"],"crossmark-restriction":false},"short-container-title":["J Clin Transl Hepatol"],"published-print":{"date-parts":[[2022,2,28]]},"DOI":"10.14218\/jcth.2021.00131","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T04:25:00Z","timestamp":1623731100000},"page":"112-119","update-policy":"https:\/\/doi.org\/10.14218\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effectiveness of Tenofovir Alafenamide in Chronic Hepatitis B Patients with Normal Alanine Aminotransferase and Positive Hepatitis B Virus DNA"],"prefix":"10.14218","volume":"10","author":[{"given":"Wen-Kang","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Yun","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Qian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2704-2131","authenticated-orcid":false,"given":"Fan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1521-1746","authenticated-orcid":false,"given":"Jin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5334","published-online":{"date-parts":[[2021,6,15]]},"reference":[{"key":"key20210615042457_JCTH-D-21-00131-b1","unstructured":"Global Hepatitis Report 2017. Available from: http:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/"},{"issue":"3","key":"key20210615042457_JCTH-D-21-00131-b2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2471\/BLT.18.219469","article-title":"Countdown to 2030: eliminating hepatitis B disease, China","volume":"97","author":"Liu","year":"2019","journal-title":"Bull World Health Organ"},{"key":"key20210615042457_JCTH-D-21-00131-b3","unstructured":"China Primary Liver Cancer Clinical Registration Survey (CLCS) Interim Report. 22nd National Congress of Clinical Oncology and 2019 CSCO Academic Conference; 2019. Available from: http:\/\/meeting.csco.org.cn\/resource\/speaker\/2945"},{"key":"key20210615042457_JCTH-D-21-00131-b4","unstructured":"Organization WH. Global health sector strategy on viral hepatitis 2016\u20132021 2017. Available from: https:\/\/www.who.int\/hepatitis\/strategy2016-2021\/ghss-hep\/en\/"},{"issue":"12","key":"key20210615042457_JCTH-D-21-00131-b5","first-page":"938","article-title":"Chinese Society of Infectious Diseases CMA, Chinese Society of Hepatology CMA.The guidelines of prevention and treatment for chronic hepatitis B (2019 version)","volume":"27","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"1","key":"key20210615042457_JCTH-D-21-00131-b6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"issue":"4","key":"key20210615042457_JCTH-D-21-00131-b7","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"key20210615042457_JCTH-D-21-00131-b8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"European Association for the Study of the Liver, European Association for the Study of the Liver.EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"issue":"2","key":"key20210615042457_JCTH-D-21-00131-b9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/apt.15311","article-title":"High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation","volume":"50","author":"Choi","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"key20210615042457_JCTH-D-21-00131-b10","journal-title":"Poster 809: Risk of HCC in patients with HBV infection with and without HIV co-infection: a US administrative claims analysis. American Association For The Study Of Liver Diseases, AASLD; 2020"},{"issue":"10","key":"key20210615042457_JCTH-D-21-00131-b11","first-page":"741","article-title":"Alanine aminotransferase normalization with antiviral therapies in hepatitis B","volume":"27","author":"Yang","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"5","key":"key20210615042457_JCTH-D-21-00131-b12","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/gutjnl-2017-314904","article-title":"High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B","volume":"67","author":"Kim","year":"2018","journal-title":"Gut"},{"issue":"7","key":"key20210615042457_JCTH-D-21-00131-b13","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/ajg.2009.187","article-title":"Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus","volume":"104","author":"Chu","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"key20210615042457_JCTH-D-21-00131-b14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/apt.12590","article-title":"Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase <\/= 40 IU\/L and significant hepatic fibrosis","volume":"39","author":"Chao","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"key20210615042457_JCTH-D-21-00131-b15","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jhep.2011.11.030","article-title":"Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review","volume":"57","author":"Papatheodoridis","year":"2012","journal-title":"J Hepatol"},{"issue":"12","key":"key20210615042457_JCTH-D-21-00131-b16","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/jgh.12327","article-title":"Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination","volume":"28","author":"Wong","year":"2013","journal-title":"J Gastroen Hepatol"},{"issue":"5","key":"key20210615042457_JCTH-D-21-00131-b17","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"issue":"7","key":"key20210615042457_JCTH-D-21-00131-b18","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/liv.14482","article-title":"Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B","volume":"40","author":"Ogawa","year":"2020","journal-title":"Liver Int"},{"issue":"7","key":"key20210615042457_JCTH-D-21-00131-b19","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s10620-019-05489-7","article-title":"Efficacy and safety of tenofovir disoproxil fumarate in treatment-naive patients with chronic hepatitis B in Korea","volume":"64","author":"Kwon","year":"2019","journal-title":"Digest Dis Sci"},{"issue":"5","key":"key20210615042457_JCTH-D-21-00131-b20","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","article-title":"Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection","volume":"60","author":"Buti","year":"2015","journal-title":"Digest Dis Sci"},{"issue":"9","key":"key20210615042457_JCTH-D-21-00131-b21","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/MCG.0000000000000544","article-title":"Histologic disease in Chinese chronic hepatitis B patients with low viral loads and persistently normal alanine aminotransferase levels","volume":"50","author":"Wang","year":"2016","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"key20210615042457_JCTH-D-21-00131-b22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s12072-021-10153-2","article-title":"High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B","volume":"15","author":"Duan","year":"2021","journal-title":"Hepatol Int"},{"issue":"4","key":"key20210615042457_JCTH-D-21-00131-b23","doi-asserted-by":"crossref","first-page":"6632","DOI":"10.1002\/jcb.27959","article-title":"Management of individuals with chronic hepatitis B virus infection and persistent normal or mildly elevated aminotransferase levels","volume":"120","author":"Yan","year":"2019","journal-title":"J Cell Biochem"},{"issue":"9","key":"key20210615042457_JCTH-D-21-00131-b24","doi-asserted-by":"crossref","first-page":"e0203312","DOI":"10.1371\/journal.pone.0203312","article-title":"Characterization and assessment of HBV chronically infected patients: identification of those eligible for treatment in the South West region of Cameroon","volume":"13","author":"Tufon","year":"2018","journal-title":"Plos One"},{"issue":"3","key":"key20210615042457_JCTH-D-21-00131-b25","first-page":"182","article-title":"Chinese Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Disease and Chinese Society of Hepatology, Chinese Medical Association; Liver Disease Committee of Chinese Research Hospital Association.Consensus on clinical application of transient elastography detecting liver fibrosis: a 2018 update","volume":"27","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"2","key":"key20210615042457_JCTH-D-21-00131-b26","doi-asserted-by":"crossref","first-page":"e00299","DOI":"10.14309\/ctg.0000000000000299","article-title":"Cost-effectiveness analysis of antiviral therapy for untreated minimally active chronic hepatitis B to prevent liver disease progression","volume":"12","author":"Lee","year":"2021","journal-title":"Clin Transl Gastroenterol"},{"key":"key20210615042457_JCTH-D-21-00131-b27","doi-asserted-by":"crossref","first-page":"gutjnl-2020-321309","DOI":"10.1136\/gutjnl-2020-321309","article-title":"Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B","author":"Kim","year":"2020","journal-title":"Gut"}],"container-title":["Journal of Clinical and Translational Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.xiahepublishing.com\/2310-8819\/JCTH-2021-00131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:20:23Z","timestamp":1783707623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.xiahepublishing.com\/2310-8819\/JCTH-2021-00131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,15]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,21]]},"published-print":{"date-parts":[[2022,2,28]]}},"alternative-id":["10.14218\/JCTH.2021.00131"],"URL":"https:\/\/doi.org\/10.14218\/jcth.2021.00131","relation":{},"ISSN":["2225-0719","2310-8819"],"issn-type":[{"value":"2225-0719","type":"print"},{"value":"2310-8819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,15]]}}}